The expansion at the company’s Gillingham, UK, site, worth EUR 9 million (approximately US$10.5 million), will improve the company’s distribution capabilities.
MilliporeSigma announced on July 2, 2018 that it plans to expand its Gillingham, UK, distribution center with a EUR 9 million (approximately US$10.5 million) investment.
The investment will improve the company’s distribution capabilities. The company’s plans to increase the existing distribution footprint by 5250 square meters was approved by the local planning authority in June 2018. The new building will add to the site’s existing 9500-square-meter facility.
According to the company, the new facility will serve as the primary distribution center for the UK and is expected to open in early 2019.
The Gillingham site distributes more than 1.9 million units of products each year to support the life-science industry across the UK as part of the company’s global supply chain. The site supplies the pharmaceutical industry, biotechnology companies, research institutes, and academic centers with biochemical and chemical reagents, laboratory supplies, and testing services. The distribution center receives nearly half a million orders each year, nearly 98% of which are shipped the same day they are received, the company reports.
Source: MilliporeSigma
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.